Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

Zymeworks Inc. (ZYME) presented Phase 1 data for ZW191, an antibody-drug conjugate, at ESMO Congress 2026. ZW191 showed a 64.5% objective response rate in high-grade serous platinum-resistant ovarian cancer patients at 6.4 mg/kg. The median duration of response was not yet reached, with a 61% six-month progression-free survival rate. Zymeworks plans to continue clinical development and explore strategic collaborations.

Original reporting
Published Oct 24, 2026, 6:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 — source image
Decision brief

The 30-second read

$ZYMEBullishMed
01

Why it matters

The Phase 1 readout provides the first quantitative efficacy signal for ZW191, a novel ADC targeting folate receptor‑alpha, which could accelerate partnership talks and boost the company's valuation.

02

Market read

The announcement is likely to move ZYME stock and may influence sentiment toward the broader ADC and oncology biotech space.

03

What to watch

The upcoming need for a larger, randomized Phase 2 trial and potential competition from other ADCs may temper immediate upside.

Relevance 8/10Novelty 8/10Timing: ahead of the investor call on Oct 27 2026

Background

Zymeworks is a publicly traded biotech (Nasdaq: ZYME) developing multifunctional therapeutics. The data were disclosed at the European Society for Medical Oncology (ESMO) Congress 2026.

Company-level read

Ticker impact

$ZYMEBullishHigh confidence
Context

Zymeworks presented new Phase 1 data for its FRα‑targeting ADC ZW191, reporting a 64.5% confirmed objective response rate in heavily pretreated ovarian cancer patients.

Expected impact

likely upside as investors price in the compelling response rates and favorable safety profile.

Evidence & confidence

Phase 1 data are the first public efficacy readout for ZW191; the high response rates across FRα expression levels are material for a biotech with a pipeline focus, prompting re‑rating and potential partnership interest.

Market effects

Positive data may lift other oncology‑focused biotech stocks and reinforce confidence in ADC platforms.

U.S. biotech investors are likely to react, with potential spill‑over to Canadian and European biotech markets.

Advances in FRα‑targeted therapies could affect global ovarian‑cancer treatment strategies and related pharmaceutical partnerships.

Counterpoint

If the durability of responses does not translate into later‑stage trials, the early hype could reverse, leading to a sell‑off.

Key entities

  • Zymeworks Inc.

    Biotech developer of ZW191 ADC.

  • ZW191

    FRα‑targeting antibody‑drug conjugate in Phase 1 trial.

Related articles

$ZYMEHighAI 9/10

Zymeworks Inc. (ZYME): Reports Third Quarter 2026 Financial Results

Zymeworks Inc. (ZYME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results • 2026 financial guidance raised to a total revenue range of $337 million to $351 million (previously between $278 million and $292 million) and an Adjusted EBITDA range of $176 million to $190 m

$ZYMEMedAI 8/10

Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal

Zymeworks (ZYME) gained attention due to Phase 1 trial data for ZW191 in ovarian cancer and a licensing deal with Roche for ZW209. The stock has seen significant returns: 19.8% in 1 month, 28.2% in 3 months, 65.9% in 1 year, and 4x in 3 years. Analysts debate its valuation, with some seeing it as 27% undervalued at a fair value of $41.50, while others note its high P/B ratio of 26.6x compared to peers.

$ZYMEMedAI 9/10

Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside

Zymeworks presented updated trial results for ZW191, an ovarian cancer treatment, showing 65% and 55% response rates at 6.4 mg/kg and 9.6 mg/kg doses, respectively. The company plans to seek external funding for further development. Zymeworks also highlighted positive data from a partner's study of Ziihera in gastroesophageal cancer. Management discussed strategic plans for R&D, partnerships, and capital allocation.

$ZYMEMed

Truist raises Zymeworks stock price target on pipeline progress

Truist Securities raised its price target for Zymeworks Inc. (NASDAQ:ZYME) to $35, citing pipeline progress and partnerships. The stock is up 53.6% over the past year, with a consensus Buy rating and 46% upside potential. Zymeworks recently acquired Theravance Biopharma and partnered with Roche for ZW209, with analysts highlighting positive developments and raising price targets.